- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03827343
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or autoimmune type reactions resulting from activation of the immune system. Referred to as immune related adverse events (irAEs), these adverse events may require systemic immunosuppression or have other consequences and present unique management challenges. Specific to CAR T-cell and other adoptive cell therapies is the constellation of symptoms referred to as cytokine release syndrome (CRS), which can range in severity from mild to severe, and can require both cytokine directed blockade and/or systemic immunosuppression to ameliorate the side effects. While side effects may be unique to each individual immunotherapy, and may also be patient specific, cumulative experience will help to inform toxicity profiles and improve management of side effects and overall outcomes.
Given the number of immunotherapeutic approaches at the NCI, the primary goal of this protocol is to facilitate retrospective chart review of various immunotherapy trials at the NCI used in the treatment of cancer to comprehensively study toxicity profiles. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected on the individual treatment protocols and is available in CRIS records or protocol specific databases.
Data will only be collected from treatment protocols where the PI has given permission for use of the data on the trial the subject was enrolled on. This protocol will be amended to incorporate new research objectives and new protocols as necessary....
Study Overview
Status
Detailed Description
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or autoimmune type reactions resulting from activation of the immune system. Referred to as immune related adverse events (irAEs), these adverse events may require systemic immunosuppression or have other consequences and present unique management challenges. Specific to CAR T-cell and other adoptive cell therapies is the constellation of symptoms referred to as cytokine release syndrome (CRS), which can range in severity from mild to severe, and can require both cytokine directed blockade and/or systemic immunosuppression to ameliorate the side effects. While side effects may be unique to each individual immunotherapy, and may also be patient specific, cumulative experience will help to inform toxicity profiles and improve management of side effects and overall outcomes.
Given the number of immunotherapeutic approaches at the NCI, the primary goal of this protocol is to facilitate retrospective chart review of various immunotherapy trials at the NCI used in the treatment of cancer to comprehensively study toxicity profiles. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected on the individual treatment protocols and is available in CRIS records or protocol specific databases. Data will only be collected from treatment protocols where the PI has given permission for use of the data on the trial the subject was enrolled on or from standard of care protocols. This protocol will be amended to incorporate new research objectives and new protocols as necessary.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- Retrospective chart review of various immunotherapy trials at the NCI used in the treatment of cancer to comprehensively study toxicity profiles. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected on the individual treatment protocols and is available in CRIS records or protocol specific databases.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To develop a retrospective study to allow for comparison of immunotherapy related toxicity profiles and risk factors across a set of protocols in the NCI.
Time Frame: 2 years
|
Summary of immunotherapy related toxicity profiles and risk factors across a set of protocols in the NCI.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall and relapse free survival
Time Frame: 2 years
|
Summary of overall and relapse free survival and transplant associated toxicities for patients undergoing HSCT following CAR-T cell therapy
|
2 years
|
Evaluate the incidence, risk factors for, and treatment of HLH/MAS in patients who receive CAR-T cell therapy
Time Frame: 2 years
|
Incidence and risk factors for, and treatment of HLH/MAS in patients who receive CAR-T cell therapy
|
2 years
|
Evaluate infectious complications and their risk factors in patients who receive CAR-T cell therapy for cancer
Time Frame: 2 years
|
Summary of infectious complications and their risk factors in patients who receive CAR-T cell therapy for cancer
|
2 years
|
Incidence and time to resolution
Time Frame: 2 years
|
Incidence of and time to resolution of grade 3 and 4 cytopenias post-CAR T-cell therapy in those who achieve a complete remission.
|
2 years
|
Incidence of end organ toxicities
Time Frame: 2 years
|
Incidence of grade 3 and 4 end organ toxicities experienced within the first 30 days of CAR T-cell therapy and includes associations between pre-CAR organ function as well as post-CAR response to such toxicities as well as validate the CAR-Comorbidity Index as predictive model of CRS severity
|
2 years
|
Evaluate response and toxicity profile of second CAR T-cell infusions
Time Frame: 2 years
|
Summary of factors associated with response to second CAR T-cell infusion
|
2 years
|
Evaluate impact of race/ethnicity and obesity on CAR T-cell outcomes
Time Frame: 2 years
|
Summary of response and toxicity profiles in patients based on race/ethnicity and also in those who are obese compared to those who are not.
|
2 years
|
Evaluate impact of cryopreservation on outcomes following CAR T-cell infusion
Time Frame: 2 years
|
Summary of cryopreservation and patients' outcomes following CAR T-cell infusion
|
2 years
|
Evaluate outcomes for patients with ALL and Down Syndrome following CAR T-cell therapy
Time Frame: 2 years
|
Summary of outcomes of patients with ALL and Down Syndrome who have received CAR T-cell therapy
|
2 years
|
Evaluate absolute lymphocyte count following lymphodepleting chemotherapy
Time Frame: 2 years
|
Summary of absolute lymphocyte count across lymphodepleting regimens
|
2 years
|
Evaluate relationship between clinical variable and apheresis and manufacturing products
Time Frame: 2 years
|
Summary of clinical variables and apheresis and manufacturing products
|
2 years
|
Evaluate incidence of hypertension, identify risk factors for development of hypertension, summarize medical management in CAR setting, and identify complications
Time Frame: 2 years
|
Summary of incidence of hypertension, risk factors, medical management and complications
|
2 years
|
Describe baseline demographics, prior treatment characteristics and outcomes based on patients who are referred to CAR T-cell program
Time Frame: 2 years
|
Summary of demographics, prior treatment and outcomes for patients referred to CAR T-cell program
|
2 years
|
Incidence of pre-infusion BCA and use of BCA as a prognostic marker for CAR T-cell associated toxicity and efficacy
Time Frame: 2 years
|
Incidence of BCA pre-infusion and use as a prognostic marker for CAR T-cell associated toxicity and efficacy
|
2 years
|
Presence and durability of CD72 expression in both B-ALL and normal B-ALL/hematogones
Time Frame: 2 years
|
Summary of CD72 expression in both B-ALL and normal B-ALL/hematogones and evaluate use as prognostic marker for CAR T-cell associated toxicity and efficacy
|
2 years
|
Evaluate interventions, documentation of care goals, and use of palliative care consultation or other symptom management
Time Frame: 2 years
|
Summary of interventions, documentation of care goals, and use of palliative care consultation or other symptom management for patients treated with CAR T-cell therapy
|
2 years
|
Evaluate long-term outcomes of survivors who received CAR T-cell therapy
Time Frame: 2 years
|
Summary of long-term outcomes of survivors who received CAR T-cell therapy
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nirali N Shah, M.D., National Cancer Institute (NCI)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999919044
- 19-C-N044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macrophage Activation Syndrome
-
Gunnar LachmannCompletedHemophagocytic Lymphohistiocytosis (HLH) | Macrophage Activation Syndrome (MAS) | Hemophagocytic Syndromes
-
Beijing Friendship HospitalNot yet recruitingMacrophage Activation Syndrome
-
University of Alabama at BirminghamActive, not recruitingMacrophage Activation SyndromeUnited States
-
Peking University People's HospitalUnknownMacrophage Activation SyndromeChina
-
University Hospital, RouenUnknown
-
Hellenic Institute for the Study of SepsisCompletedSepsis | Macrophage Activation SyndromeGreece
-
Amrita Institute of Medical Sciences & Research...UnknownLymphohistiocytosis, Hemophagocytic | Macrophage Activation SyndromeIndia
-
National Institute of Allergy and Infectious Diseases...RecruitingLymphohistiocytosis, Hemophagocytic | Macrophage Activation Syndrome | Secondary Hemophagocytic Lymphohistiocytosis | Hyperinflammatory SyndromesUnited States
-
FSD Pharma, Inc.TerminatedMast Cell Activation Syndrome | Mast Cell Activation Disorder IdiopathicCanada, United States
-
Oxford University Clinical Research Unit, VietnamHospital for Tropical Diseases, Ho Chi Minh City, VietnamRecruitingCytokine Storm | Dengue | Severe Dengue | Macrophage Activation Syndrome | Anakinra | Dengue With Warning Signs | Anti-inflammatory Agents | Hyperinflammatory Syndrome | Immuno-modulationVietnam